Gross pathology

2021 Geographic Atrophy (Ophthalmology) Drugs in Development Report - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Health, Pharmaceutical, Branches of biology, Health sciences, Anatomy, Gross pathology, Anatomical pathology, Atrophy, Androgen receptor, Geographic atrophy, Mechanism of action

The "Geographic Atrophy (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Geographic Atrophy (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Geographic Atrophy (Ophthalmology) therapeutics and enlists all their major and minor projects.

NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Thursday, July 22, 2021
Anatomy, Gross pathology, Geographic atrophy, Atrophy, Medical specialties

Completing enrollment in CATALINA is an important milestone for NGM and the patients with geographic atrophy that we hope to serve.

Key Points: 
  • Completing enrollment in CATALINA is an important milestone for NGM and the patients with geographic atrophy that we hope to serve.
  • We are highly encouraged by the programs progress to date and for the potential of NGM621 to change the disease trajectory for geographic atrophy patients.
  • The Phase 2 CATALINA study enrolled a total of 320 patients with geographic atrophy, more than the originally planned 240 patients.
  • The Phase 2 CATALINA study enrolled 320 patients diagnosed with geographic atrophy in one or both eyes.

Laborie Medical Technologies, in Partnership with Urotronic Inc., Announces Completion of First Optilume® Procedures in the National Health Service (NHS), United Kingdom (UK)

Retrieved on: 
Tuesday, June 22, 2021
Medical specialties, Medicine, Anatomy, Medical terminology, Urethral stricture, Gross pathology, Urinary system, Urethra, Stenosis, Minimally invasive procedure, Urethroplasty, Ureteric stricture

In October 2020, LABORIE and Urotronic Inc. (Urotronic), entered into a multi-faceted, strategic partnership1.

Key Points: 
  • In October 2020, LABORIE and Urotronic Inc. (Urotronic), entered into a multi-faceted, strategic partnership1.
  • Following the successful procedures, Dr. Patel commented, "We're delighted to be pioneering the Optilume Drug Coated Balloon technology to advance patient care for the treatment of urethral stricture.
  • Optilume offers a minimally invasive alternative with the potential of fewer recurrences that is often seen in existing endoscopic treatment options.
  • Strictures can be caused by infections, trauma, and other medical procedures that injure the lining of the urethra and can significantly impact patients' quality of life.

Tummy Warrior Postnatal Fitness is Transforming Mom Bods with Core Strength

Retrieved on: 
Friday, May 28, 2021
Articles, Diastasis, Gross pathology, Fitness, Core stability, Warrior

For Tummy Warrior founder and Diastasis Specialist Becky Choi, the gap in her abdominal wall left her feeling lost.

Key Points: 
  • For Tummy Warrior founder and Diastasis Specialist Becky Choi, the gap in her abdominal wall left her feeling lost.
  • As a mom of two,Becky was determined to return to her confidence, not only for herself but also for her family.
  • Her mission for core strength began, and it has allowed her to cultivate a brand dedicated to helping new mothers build their confidence from the core up.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/tummy-warrior-postnatal-fitness-...
    SOURCE Tummy Warrior Postnatal Fitness Inc.

The Lisa Foundation Appoints New Executive Director to Continue Leading the Fight Against Brain Aneurysms

Retrieved on: 
Tuesday, May 25, 2021
Vascular diseases, Aneurysm, Gross pathology

She is the first survivor to take over a leadership role for an organization in the Brain Aneurysm industry.

Key Points: 
  • She is the first survivor to take over a leadership role for an organization in the Brain Aneurysm industry.
  • "I am truly honored to continue Todd's mission of advocating and being a voice for the Brain Aneurysm community.
  • Debbie brings a strong background working in nonprofit to her new role at The Lisa Foundation.
  • The Lisa Foundation, a 501(c)(3), is a private funder of Brain Aneurysm initiatives that directly or indirectly support awareness, education, research and survivor support in the US.

2021 Report on the Global Spinal Muscular Atrophy Market - Epidemiology and Patient Flow - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Surgery, Health, Physical therapy, Neurological disorders, Branches of biology, Medical specialties, Motor neuron diseases, Neuromuscular Disorders, Gross pathology, Neurogenetic disorders, Muscle atrophy, Atrophy, Draft:Hamano Tsukamoto Syndrome, Spinal muscular atrophies

b'The "Global Spinal Muscular Atrophy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Spinal Muscular Atrophy epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Spinal Muscular Atrophy Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Spinal Muscular Atrophy epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Spinal Muscular Atrophy patients, history of the disease at the population level (Spinal Muscular Atrophy prevalence, Spinal Muscular Atrophy incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSpinal Muscular Atrophy patient flow: Spinal Muscular Atrophy prevalence, diagnosed, and drug-treated patients\nDemographics: Spinal Muscular Atrophy patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Spinal Muscular Atrophy market sizing, assessing market potential, and developing drug forecast models\nIdentify Spinal Muscular Atrophy patients segments through age groups, gender, and disease sub-types\nEvaluate Spinal Muscular Atrophy market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005653/en/\n'

Worldwide Neurovascular Devices Industry to 2029 - Featuring Penumbra, Phenox and Stryker Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Medical devices, Health, Medical specialties, Interventional radiology, Medicine, Clinical medicine, Vascular diseases, Aneurysm, Gross pathology, Embolization, Stroke, Stent, Neurovascular bundle, Alexander L. Coon

Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.

Key Points: 
  • Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.
  • As per the Internet Stroke Center statistics, around 75% of strokes take place in the age group of 60-65.
  • For example, with the introduction of new flow diversion stent technique, the need to treat complex aneurysms with bypasses has fallen down.
  • However, lack of skilled neurologists in hospitals is limiting the growth of neurovascular devices market.\n'

Worldwide Intracranial Aneurysm Industry to 2025 - Featuring Medtronic, B. Braun and Penumbra Among Others

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Neurosurgery, Angiology, Cardiovascular system, Vascular diseases, Interventional radiology, Aneurysm, Gross pathology, Endovascular coiling, Surgery, Vascular surgery, Intracranial aneurysm

Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.

Key Points: 
  • Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.
  • Amongst all, the ruptured aneurysm segment holds the highest market share.\nBy Treatment Type, the market is classified as Medication and Surgery.
  • Amongst all, the surgery segment holds the highest market share.\nBy End-user, the market is classified as Hospital & Clinics, Diagnostic Centers, and others.
  • Amongst all, the hospital segment holds the highest market share.\nBy Geography, North America is projected to lead the market.\n1.

EnsiteVascular receives FDA market clearance for SiteSeal™ SV vascular closing device's second indication

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Health care, Clinical medicine, Interventional cardiology, Gross pathology, Brachial artery, Radial artery, Brachial, Vascular closure device, Aneurysm, Federal Food, Drug, and Cosmetic Act

b'OLATHE, Kan., April 20, 2021 /PRNewswire-PRWeb/ -- EnsiteVascular announces today it received its second U.S. Food and Drug Administration (FDA) market clearance for the company\'s SiteSeal SV (small vessel) VCD to achieve hemostasis of the brachial artery after a transbrachial endovascular procedure.\nThe FDA\'s market clearance occurred once the agency reviewed EnsiteVascular\'s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure.

Key Points: 
  • b'OLATHE, Kan., April 20, 2021 /PRNewswire-PRWeb/ -- EnsiteVascular announces today it received its second U.S. Food and Drug Administration (FDA) market clearance for the company\'s SiteSeal SV (small vessel) VCD to achieve hemostasis of the brachial artery after a transbrachial endovascular procedure.\nThe FDA\'s market clearance occurred once the agency reviewed EnsiteVascular\'s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure.
  • Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.\nSiteSeal SV is a new closure device designed for closure of small arterial vessels, specifically brachial, radial and pedal.
  • These include pseudo aneurysms, thrombosis and excess bleeding, with over 60% requiring surgical repair," says Rex Teeslink, M.D., medical director, EnsiteVascular.\n"Currently, there is no other device with FDA market clearance for closure of brachial artery access sites.
  • In addition, SiteSeal SV leaves nothing behind within the vessel, vessel wall or surrounding soft tissues.

Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)

Retrieved on: 
Thursday, April 15, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Neurological disorders, Branches of biology, Neurodegenerative disorders, Motor neuron diseases, Neuromuscular Disorders, Gross pathology, Spinal muscular atrophy, Neurogenetic disorders, Amyotrophic lateral sclerosis, Atrophy, Muscle atrophy, Risdiplam, Evrysdi™ (risdiplam), SMA, Genentech in Neuroscience, Genentech

The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support.

Key Points: 
  • The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support.
  • The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation*.
  • Basil Darras, Professor of Neurology at Harvard Medical School and Director of the Spinal Muscular Atrophy Program at Boston Children's Hospital.
  • Part 2 (n=180) evaluated motor function using total score of Motor Function Measure 32 (MFM-32) at 12 months.